| Type: | combo |
| Component1: | Lamivudine |
| Class1: | Reverse-transcriptase inhibitor |
| Component2: | Raltegravir |
| Class2: | Integrase inhibitor |
| Tradename: | Dutrebis |
| Legal Us: | Rx-only |
| Routes Of Administration: | Oral |
| Atc Prefix: | J05 |
| Atc Suffix: | AR16 |
| Cas Number: | 2446160-46-7 |
| Kegg: | D10754 |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It contains lamivudine and raltegravir. It is taken by mouth. Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. It was approved for medical use in the United States in 2015.[1] [2]
Lamivudine/raltegravir is not available in the United States.[3]